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Difficult-to-treat asthma
— an uncontrolled disease.
Is there any relation to the experience
from palliative medicine?
Abstract
Background and aim. Difficult-to-treat asthma is characterized by uncontrolled symptoms occurring in
spite of intensive treatment (corticosteroids and long-acting b2-agonists) for at least 6 months and is
connected with severe obturation in the bronchotracheal tree. It still creates an important global medical
and economical problem. The aim of the study was to evaluate the occurrence of persistent symptoms,
exacerbating factors and co-morbidities in patients with difficult-to-treat asthma. It was also a challenging
idea to apply palliative medicine to help patients with this type of asthma.
Material and methods. Twenty-seven patients (21 women and 6 men, ages ranging from 23 to 60)
diagnosed with difficult-to-treat asthma were included in the study. Data were collected from the internet
database of severe, difficult-to-treat asthma, introduced to the Department of Allergology in 2005. All
patients’ spirometries and additional factors were assessed.
Results. The median predicted value of FEV1 was 55% (range: 34–104%) while 18 patients had FEV1 lower
than the 60% predicted value. All patients suffered from dyspnoea, chronic cough and wheezing and had
additional factors escalating the symptoms of asthma. The most important factor which leads to exacerba-
tion was long-term stress and rhinitis. Twelve (45%) patients from this group have poor tolerance of
exercise. In spite of intensive treatment, 17 (65%) patients constantly overused short-acting beta-agonists
(SABA) and all had long-term treatment with oral steroids. In most cases, co-morbidities were recognized:
obesity and hypertension.
Conclusions. This study showed that the role of additional factors and co-morbidities plays a significant
part in the course of asthma. It seems to be necessary to introduce a unified system of registering and
managing patients with severe and difficult-to-treat asthma. That palliative care is very important for
selected patients with chronic uncontrolled cough or dyspnoea should be a subject for newly planned
clinical trials.
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Introduction
“Asthma is an inflammatory disorder of the air-
ways, which involves several inflammatory cells and
multiple mediators that result in characteristic patho-
physiological changes. In ways which are still not
well understood, the pattern of inflammation is
strongly associated with airway hyperresponsiveness
and asthma symptoms” [1].
The latest version of the GINA guidelines (No-
vember 2007) introduced several changes to those
already existing [1], such as the new classification of
asthma based on the control of symptoms and the
definition of difficult-to-treat asthma. According to
this description, difficult-to-treat asthma is charac-
terized by uncontrolled symptoms occurring in spite
of intensive (stage IV) treatment for at least 6
months. Usually, respiratory function measured by
spirometry shows severe obturation of the airways
(FEV1 < 60% of predicted value).
The severe stage of asthma is an important med-
ical and economical problem. Frequent exacerba-
tions associated with this type of asthma and persis-
tent symptoms requiring constant management gen-
erate significant costs, as high as 1–2% of the total
medical budget in  western European countries [1].
In 1994, European Network for Understanding
of Severe Asthma (ENFUMOSA) was introduced to
work on severe and difficult-to-treat asthma [2]. The
results of researches undertaken by the group
showed that the risk factors for severe asthma in-
clude gender. Females with higher body mass index
(BMI) and hypertension were especially at risk. Oth-
er factors determining the course of the disease in
women were chronic sinusitis, the perimenopausal
period, aspirin intolerance and physical activity. In
men, physical activity, stress and aspirin intolerance
exacerbated asthma [2]. Resistance to steroids was
also underlined as a factor contributing to the se-
verity of the disease [3]. By contrast, true steroid
resistance caused by the polymorphic variant of the
gene coding for the glicocorticosteroid receptor is a
rare entity. Much more frequently, asthma is “sim-
ply” a steroid-dependent disease, requiring the use
of systemic (oral) treatment. Recently, anti-IgE treat-
ment has been introduced in a group with severe
asthma [4]. This new agent enables improvement to
the quality of life.
The aim of the study was to assess the occur-
rence of persistent symptoms, factors exacerbating
the course of the disease and co-morbidities in pa-
tients with severe, difficult-to-treat asthma. We also
considered the idea that there is a need to imple-
ment some experience from palliative medicine into
the management of this group of patients.
Material and methods
The study group comprised 27 patients with se-
vere, difficult-to-treat asthma, treated at the Aller-
gology Department, Medical University, Gdansk be-
tween 2005–2007. There were 21 women and six
men, aged from 23 to 60; median age: 35 years.
Median FEV1 was 55% of the predicted value (range:
34–104%), and 18 patients had FEV1 lower than the
60% predicted value. The mean time from diagnosis
to the time of the assessment was 21.6 years, range:
from 7 to 50 years. At the time of the assessment
bronchial obstruction reversibility was present in 10
patients. Data were collected from the database of
severe, difficult-to-treat asthma, introduced to the
Department of Allergology in 2005. The Local Ethic
Committee has approved the study (NKEBN/369/
/2005).
Results
All patients suffered from dyspnoea, chronic
cough and wheezing. Twelve (45%) underline poor
tolerance of exercise (Table 1). In spite of intensive
treatment, 17 (65%) patients constantly overused
short-acting beta-agonists (SABA) and all had long-
term treatment with oral steroids.
All patients had additional factors escalating their
symptoms and exacerbating the course of the dis-
ease (Table 2): stress and allergic rhinitis being the
most common. They also had a number of co-mor-
bidities (Table 3), the most prevalent being obesity
and hypertension.
Discussion
Whether palliative medicine has any connection
with the treatment of asthma remains open. Cur-
rently, the answer to this question is usually “No”.
However, the clinical course of severe and difficult-
to-treat asthma resembles the course of severe chronic
obstructive pulmonary disease (COPD). The need for
palliative care for the latter has been discussed for
the last decade. Some authorities indicate that chronic
severe pulmonary symptoms significantly decrease
the quality of life of patients with COPD, having a
strong impact on all its aspects [5]. Furthermore, it
has been stressed that patients with severe COPD
require the same terminal care and support as pa-
tients with advanced malignancies [6–8].
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Our small study including patients with severe
and difficult-to-treat asthma showed that, in spite
of intensive treatment, persistent disturbing pulmo-
nary symptoms are common in this group of pa-
tients. Thus, if asthmatic patients suffer for a long
time from dyspnoea and cough resistant to the rec-
ommended and widely accepted treatment modali-
ties, some propositions from palliative medicine
might be taken into consideration. One of them is
the administration of nebulized opioids. Systematic
analysis of randomized controlled clinical trials has
not proved the efficacy of inhaled opioids in con-
trolling dyspnoea or exercise tolerance in patients
with COPD or idiopathic pulmonary fibrosis [9]. How-
ever, predominantly low-level clinical evidence sup-
ports inhaled opioids for the palliation of dyspnoea
in patients with advanced cancer and cystic fibrosis
[10–12]. The fundamental and still unanswered ques-
tion is whether opioids act locally in the respiratory
tract. We recently performed an immunohistochem-
ical visualization of opioid receptors in the human
airways and revealed their presence in the tracheal
and bronchial epithelium and in sensory unmyeli-
nated nerves containing peptides [13]. Previous func-
tional studies showed that in vitro opioids, by inhib-
iting proinflammatory neurotransmitters released
from sensory nerves, reverse the constriction of iso-
lated bronchi and diminish mucus production [14–
–21]. All these data support the idea that opioids,
by local action, may decrease the dyspnoea and
cough related to neurogenic inflammation, thus sug-
gesting their potential benefit for asthma. However,
asthma creates some specific problems. One of them
is connected with the fear of the bronchospasm due
to the histamine release by morphine. It has been
suggested that only higher doses of morphine may
evoke such a reaction on the mast cells of the respi-
ratory airways [20]. Otulana and coworkers investi-
gated the safety and pharmacokinetics of inhaled
morphine in 20 subjects with moderate-to-severe
asthma [22]. Morphine was well-tolerated and
caused no clinically significant bronchoconstriction
in most patients. Four subjects who experienced a
Table 1. Patients’ (n = 27) characteristic and
chronic symptoms occurrence
Characteristic Number
Gender
Men 6
Women 21
Age
Mean 46.8
Range 23–60
Years from diagnosis
Median 21.6
Range 7–50
FEV1
Median 55%
Range 34–104%
Bronchial obstruction reversibility 10
(at the time of assessment)
Eosiniphilia 1
Total IgE
Median
Range 10–757
Positive SPT 6
Permanent use of oral steroids 27
SABA overuse Mean = 4 puffs/day
(17 patients used ≥ 2 ¥ day
Chronic dyspnoea 26
Chronic cough 26
Poor tolerance of exercise 12
Wheezing 26
Gender
Men 6
Women 21
Age
Mean
Range 23–60
FEV1 — one second forced expiratory volume; SPT — skin prick testing;
SABA — short-acting beta-agonists
Table 2. Factors escalating symptoms of asthma
Factor Number
Cigarette smoking 10
Chest X-ray abnormalities 2
Allergic rhinitis 20
Chronic sinusitis 4
GERD 17
Stress 25
Vocal cords dysfunction 5
Aspirin (NSAIDs) intolerance 10
Co-existing COPD 0
GERD — gastroesophageal reflux disease; NSAIDs — non-steroidal
anti-inflammatory drugs; COPD — chronic obstructive pulmonary
disease
Table 3. Co-morbidities
Co-morbidity Number
Overweight/obesity 15
Hypertension 11
Cardiac disease 5
Venous thrombosis 0
Osteopenia/osteoporosis 3
Diabetes 2
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11. Cohen SP, Dawson TC. Nebulized morphine as a treat-
ment for dyspnea in a child with cystic fibrosis. Pediatrics
2002; 110: e38–e40.
12. Kallet RH. The role of inhaled opioids and furosemide for
the treatment of dyspnea. Respiratory Care 2007; 52:
900–910.
13. Krajnik M, Mousa SA, Stein C.Opioid receptors and en-
dogenous opioids in human lung tissue [abstract]. In:
Abstracts of 11th World Congress on Pain. IASP Press,
Seattle 2005: 419.
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capsaicin-sensitive neurones in the rat trachea in vitro.
Br J Pharmacol 1991; 102: 797–800.
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tion by NK1, NK2, µ-opioid, ?2-adrenoceptor and gluco-
corticoid receptors in guinea-pig isolated perfused lung.
J Pharm Pharmacol 1998; 50: 899–905.
16. Lindström EG, Andersson RGG. Morphine modulates con-
tractile responses and neurokinin A-LI release elicited by
electrical field stimulation or capsaicin in a guinea pig
bronchial-tube preparation. Am J Respir Crit Care Med
1995; 151: 1175–1179.
17. Belvisi MG, Stretton CD, Verleden GM. Ledinham SJ,
Yacoub MH, Barnes PJ. Inhibition of cholinergic neu-
rotransmission in human airways by opioids. J Appl Physiol
1992; 72: 1096–1100.
18. Fischer AB, Undem J. Naloxone blocks endomorphin-1
but not endomorphin-2 induced inhibition of tachykin-
ergic contractions of guinea-pig isolated bronchus.
Br J Pharmacol 1999; 127: 605–608.
19. Rogers DF, Barnes PJ. Opioid inhibition of neurally me-
diated mucus secretion in human bronchi. Lancet 1989;
1 (8644): 930–932.
20. Lei YH, Rogers DF. Effects and interactions of opioids on
plasma exudation induced by cigarette smoke in guinea
pig bronchi. Am J Physiol Lung Cell Mol Physiol 1999;
276: L391–L397.
21. Karlsson JA, Lanner AS, Persson CGA. Airway opioid re-
ceptors mediate inhibition of cough and reflex bron-
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Safety and pharmacokinetics of inhaled morphine deliv-
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to-severe asthma. Int J Clin Pharmacol Ther 2004; 42:
456–462.
23. Coyne PJ, Viswanathan R, Smith TJ. Nebulized fentanyl
citrate improves patients perception of breathing, respi-
ratory rate and oxygen saturation in dyspnea. J Pain Symp-
tom Manage 2002; 23: 157–160.
24. Quigley C, Joel S, Patel N, Baksh A, Slevin M. A phase I/II
study of nebulized morphine-6-glucuronide in patients
with cancer-related breathlessness. J Pain Symptom Ma-
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25. Rutherford RM, Azher T, Gilmartin JJ. Dramatic response
to nebulized morphine in an asthmatic patient with se-
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significant drop in FEV1 recovered after a dose of
albuterol [22]. However, while the problem of po-
tential bronchoconstriction after opioids is unclari-
fied, nebulized morphine is not recommended for
asthmatic patients at present. To avoid this poten-
tial risk, other opioids have been tried, such as very
low doses of nebulized fentanyl citrate or morphine-
6-glucuronide [23, 24].
Nebulized opioids seem to be a very promising
treatment option in carefully selected cases, such as
a patient with a 16-year history of asthma who suf-
fered severe coughing, bronchospasms and greatly
reduced exercise tolerance [25]. His cough failed to
respond to all standard asthma therapy and even to
nebulized lidocaine. He was commenced on nebu-
lized morphine with a dramatic reduction in cough
and successfully treated for 2.5 years. However, our
small study also showed that the role of additional
factors and co-morbidities having an influence on
the course of asthma should be taken into account.
In summary, it seems necessary to introduce a
unified system of registering and managing patients
with severe and difficult-to-treat asthma, as was
done for patients with chronic heart diseases. Im-
plementation of palliative care for carefully selected
patients with chronic uncontrolled cough or dysp-
noea should be a subject for newly planned clinical
trials.
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